Biologic agents, such as anti-tumor necrosis factor, anti-interleukin-1, and anti-interleukin-6, target cytokines involved in the inflammatory process of JIA which are indicated in patients with JIA who do not respond to the combination of NSAID, DMARDs and/or corticosteroids [19–21]. Here, IL6 is linked to juvenile idiopathic arthritis.